

This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.



[Reference Translation]

July 14, 2023

Company name: JMS Co., Ltd.  
Name of representative: Ryuji Katsura, President and Representative Director (Securities code: 7702; Prime Market of Tokyo)  
Inquiries: Jo Sueda, Executive Officer, Head of Corporate Affairs Division (Telephone: +81-82-243-5844)

### **Notice of Changing Subsidiary's Indirectly Owned Subsidiary**

JMS Co., Ltd. hereby announces that JMS Singapore Pte. Ltd., our consolidated subsidiary, has decided to enter into an equity transfer agreement today with Asahi Kasei Medical Co., Ltd. The agreement entails the acquisition of the entire equity interest in Asahi Kasei Transfusion Technology Co., Ltd. ("AKTT"), a subsidiary of Asahi Kasei Medical Co., Ltd. Please find the details below.

#### 1. Reason for Acquisition of Equity Interest

We are currently engaged in the global manufacturing and distribution of products essential for blood management business, including blood bags used for blood preservation after blood donation and products required for blood collection and transfusion, which form a significant part of our core blood business. In many countries, including Japan, blood bags with integrated leukocyte reduction filters are utilized to prevent adverse reactions during transfusions using blood derived from blood donations. The demand for such blood bags is expected to continue growing. AKTT, leveraging the technology and know-how of Asahi Kasei Medical Co., Ltd.'s leukocyte reduction filter "Sepacell™," primarily manufactures and sells leukocyte reduction filters for the domestic market in China. To strengthen our business foundation and respond to expanding demand in a flexible and efficient manner, we have decided to acquire all of AKTT's equity interest and make it our subsidiary. This strategic move allows us to internalize the production of leukocyte reduction filters, which were previously sourced externally, and create synergies through the integrated operation with blood bags. Furthermore, by assuming a new role in the supply of leukocyte reduction filters, we aim to enhance our presence in the global blood management markets, thereby expanding our business revenue.

#### 2. Outline of Subsidiary to acquire the Equity Interest

(1) Name.	JMS SINGAPORE PTE. LTD.
(2) Location.	440 Ang Mo Kio Industrial Park 1, Singapore, 569620
(3) Job title and name of representative	Tohru Sakoda, Managing Director
(4) Business description	Manufacture, Sales, Export and import of Medical Devices and Pharmaceuticals.
(5) Capitalization.	SGD 16million (JPY 1,673million, converted 1SGD = JPY 104.58 As of June15,2023)

#### 3. Outline of Transferred Sub-subsidiary

(1) Name.	Asahi Kasei Transfusion Technology Co.,Ltd.
(2) Location.	No8 Xiangshanhe Road, Jingang Town, Zhangjiagang City, Jiangsu Province, 215632 China
(3) Job title and name of representative	Masafumi Asakawa, General Manager
(4) Business description	Development, manufacture and sale of leukocyte reduction filters for blood transfusion.

(5) Capitalization.	CNY 111.63million (JPY 2,184million)		
(6) Date established.	October 13, 1999.		
(7) Major shareholder and shareholding ratio	Asahi Kasei Medical Co., Ltd. 100%.		
(8) Relationship between the listed company and the company in question	Capital relationship	There is no capital relationship to be described.	
	Personnel relationship	There is no personnel relationship to be described.	
	Business relationship	There is no business relationship to be described.	
(9) Consolidated operating results and consolidated financial condition of the company during the last three years			
Fiscal year	Ended December 2020	Ended December 2021	Ended December 2022
Net assets	CNY 80,520,537 (JPY 1,576 million)	CNY 73,875,352 (JPY 1,446 million)	CNY 80,950,027 (JPY 1,584 million)
Total assets	CNY 85,237,570 (JPY 1,668 million)	CNY 104,667,925 (JPY 2,048 million)	CNY 122,672,295 (JPY 2,401 million)
Net sales	CNY 18,807,830 (JPY 368 million)	CNY 26,202,846 (JPY 513 million)	CNY 30,448,767 (JPY 596 million)

\*The exchange rate is JPY 19.57 per CNY, as of June 15, 2023.

\*Financial information after operating profit onward is not disclosed at the request of the counterparty.

#### 4. Outline of the Counterparty to the acquisition of Equity Interest

(1) Name.	Asahi Kasei Medical Co., Ltd.	
(2) Location.	Hibiya Mitsui Tower, 1-2, Yurakucho 1-chome, Chiyoda-ku, Tokyo	
(3) Job title and name of representative	Ken Shinomiya , Representative Director and President	
(4) Business description	Development, manufacture and sale of medical equipment	
(5) Capitalization.	JPY 3,000 million	
(6) Date established.	July 24, 1974	
(7) Net assets	JPY 76.3 billion (as of 31 March, 2022)	
(8) Total assets	JPY 99.8 billion (as of 31 March, 2022)	
(9) Major shareholder and shareholding ratio	Asahi Kasei Corp. 100%.	
(10) Relationship between the listed company and the company in question	Capital relationship	There is no capital relationship to be described.
	Personnel relationship	There is no personnel relationship to be described.
	Business relationship	There are business transactions between the Company and its subsidiaries.
	Applicability to related parties	There is no applicable item to be described.

#### 5. Number and Amount of Equity Interest to be Acquired and Status of Equity Interest Ownership Before and after Acquisition

(1) Ratio of equity interest before transfer	0%
(2) Ratio of equity interest to be transferred	100%.
(3) Acquisition amount	This information is not disclosed at the request of the counterparty. The acquisition price has been determined following discussions between the parties, based on a value calculation by an external expert and after reasonable consideration of the results of legal and financial investigations by external lawyers and certified public accountants.
(4) Ratio of equity interest after transfer	100.0%.

**6. Schedule**

(1) Contract signing date	July 14, 2023
(2) Share transfer date	October 31, 2023 (plan)

**7. Future Prospects**

The impact of this transaction on consolidated performance for the financial year ending March 31, 2024 is minor.

For further information, please contact.  
Corporate Strategy Office, Corporate Planning Group  
(Telephone) +81-82-243-9059  
(e-mail) pub-bpd@jms.cc